Paycom Software (PAYC) continues to be an active participant in the biotech market as evidence by various events. The company posted strong
Q1 and Q2 2024 Earnings, exceeding estimates and analysts' expectations. The reports sparked attraction from various investment firms, with
Mather Group,
Cetera Investment Advisers and
Kingsview Wealth Management increasing their holdings in the company.
CEO Chad R. Richison also sold significant amounts of shares. The continuous insider selling caused some caution among investors, despite impressive three-year earnings growth.
Paycom's revenues, however, failed to present a noticeable improvement - which might be a growing concern. Despite a temporary 4.7% drop in stock after the last earnings report, investing in
Paycom is still considered beneficial. Promisingly, Barclays have increased PAYC price target to
$167.00 and reiterated by other analysis firms.
Paycom also announced quarterly cash dividends and extended stock repurchase plans.
Paycom Software PAYC News Analytics from Mon, 29 Jan 2024 08:00:00 GMT to Sat, 10 Aug 2024 20:05:40 GMT -
Rating 5
- Innovation 6
- Information 8
- Rumor 3
